Medicines and Healthcare products Regulatory Agency (MHRA) – Implementation of medical devices future regime
On 21 October 2024, MHRA published a guidance to help medtech manufacturers comply with its updated post-market surveillance (PMS) regulation. The draft Post-Market Surveillance Statutory Instrument was laid in Parliament, and it was signed into law on 16th December 2024. These regulations will come into force following a 6-month transition period on 16 June 2025. The aim of the new regulations is to introduce clearer and more robust requirements for PMS that improve patient safety.
Please find further information here.
News reported on the 31st of January 2025 in Catapult’s regulatory round-up, read the entire report here.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (20 mai 2025). Medicines and Healthcare products Regulatory Agency (MHRA) – Implementation of medical devices future regime. ELSIBI. Consulté le 19 janvier 2026 à l’adresse https://doi.org/10.58079/13yes





